Etoposide-related cardiotoxicity in a child with haemophagocytic lymphohistiocytosis.
We report a male child with haemophagocytic lymphohistiocytosis who developed myocardial infarction after receiving etoposide. He recovered well with supportive measures and after discontinuation of etoposide. We discuss the possible mechanisms and differential diagnoses of myocardial infarction in our patient.
Escoto
Heather
H
Division of Pediatric Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Ringewald
Jeremy
J
Kalpatthi
Ram
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004562:Electrocardiography; D005047:Etoposide / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000175:diagnosis* / Q000628:therapy; D018570:Risk Assessment; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D020257:Ventricular Remodeling / Q000502:physiology; D028761:Withholding Treatment
D013256:Steroids; D005047:Etoposide; D016572:Cyclosporine